DOCSLIB.ORG

Novel GFM2 Variants Associated with Early-Onset Neurological Presentations of Mitochondrial Disease and Impaired Expression of OXPHOS Subunits

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Novel GFM2 Variants Associated with Early-Onset Neurological Presentations of Mitochondrial Disease and Impaired Expression of OXPHOS Subunits King’s Research Portal DOI: 10.1007/s10048-017-0526-4 Document Version Publisher's PDF, also known as Version of record Link to publication record in King's Research Portal Citation for published version (APA): Glasgow, R. I. C., Thompson, K., Barbosa, I. A., He, L., Alston, C. L., Deshpande, C., Simpson, M. A., Morris, A. A. M., Neu, A., Löbel, U., Hall, J., Prokisch, H., Haack, T. B., Hempel, M., McFarland, R., & Taylor, R. W. (2017). Novel GFM2 variants associated with early-onset neurological presentations of mitochondrial disease and impaired expression of OXPHOS subunits. NEUROGENETICS, 1-9. https://doi.org/10.1007/s10048-017-0526-4 Citing this paper Please note that where the full-text provided on King's Research Portal is the Author Accepted Manuscript or Post-Print version this may differ from the final Published version. If citing, it is advised that you check and use the publisher's definitive version for pagination, volume/issue, and date of publication details. And where the final published version is provided on the Research Portal, if citing you are again advised to check the publisher's website for any subsequent corrections. General rights Copyright and moral rights for the publications made accessible in the Research Portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognize and abide by the legal requirements associated with these rights. •Users may download and print one copy of any publication from the Research Portal for the purpose of private study or research. •You may not further distribute the material or use it for any profit-making activity or commercial gain •You may freely distribute the URL identifying the publication in the Research Portal Take down policy If you believe that this document breaches copyright please contact [email protected] providing details, and we will remove access to the work immediately and investigate your claim. Download date: 07. Oct. 2021 Neurogenetics https://doi.org/10.1007/s10048-017-0526-4 ORIGINAL ARTICLE Novel GFM2 variants associated with early-onset neurological presentations of mitochondrial disease and impaired expression of OXPHOS subunits Ruth I. C. Glasgow1 & Kyle Thompson1 & Inês A. Barbosa2 & Langping He1 & Charlotte L. Alston1 & Charu Deshpande2 & Michael A. Simpson2 & Andrew A. M. Morris3,4 & Axel Neu5 & Ulrike Löbel 6 & Julie Hall7 & Holger Prokisch8,9 & Tobias B. Haack9,10 & Maja Hempel11 & Robert McFarland1 & Robert W. Taylor1 Received: 22 September 2017 /Accepted: 3 October 2017 # The Author(s) 2017. This article is an open access publication Abstract Mitochondrial diseases are characterised by clini- demonstrate the effects of defective mtEFG2 function, caused cal, molecular and functional heterogeneity, reflecting their bi- by previously unreported variants, confirming pathogenicity genomic control. The nuclear gene GFM2 encodes mtEFG2, a and expanding the clinical phenotypes associated with GFM2 protein with an essential role during the termination stage of variants. mitochondrial translation. We present here two unrelated pa- tients harbouring different and previously unreported com- Keywords WES . GFM2 . Mitochondrial translation . pound heterozygous (c.569G>A, p.(Arg190Gln); c.636delA, Developmental delay . Mitochondrial disease p.(Glu213Argfs*3)) and homozygous (c.275A>C, p.(Tyr92Ser)) recessive variants in GFM2 identified by whole exome se- quencing (WES) together with histochemical and biochemical Introduction findings to support the diagnoses of pathological GFM2 var- iants in each case. Both patients presented similarly in early Mitochondrial disorders are a genetically and clinically het- childhood with global developmental delay, raised CSF lac- erogeneous group of diseases which can arise due to defects in tate and abnormalities on cranial MRI. Sanger sequencing of the oxidative phosphorylation (OXPHOS) system. The familial samples confirmed the segregation of bi-allelic GFM2 OXPHOS system comprises five multi-subunit protein com- variants with disease, while investigations into steady-state plexes—the electron transport chain (complexes I–IV) and mitochondrial protein levels revealed respiratory chain sub- ATP synthase (complex V)—which function together to gen- unit defects and loss of mtEFG2 protein in muscle. These data erate cellular energy in the form of ATP. Mitochondria possess * Robert W. Taylor 6 Department of Diagnostic and Interventional Neuroradiology, [email protected] University Medical Center Hamburg-Eppendorf, Hamburg, Germany 1 Wellcome Centre for Mitochondrial Research, Institute of 7 Department of Neuroradiology, Royal Victoria Infirmary, Newcastle Neuroscience, The Medical School, Newcastle University, upon Tyne, UK Newcastle upon Tyne NE2 4HH, UK 8 Institute of Human Genetics, Helmholtz Zentrum München, 2 ’ Department of Medical and Molecular Genetics, King sCollege Oberschleißheim, Germany London School of Medicine, London, UK 9 3 Division of Evolution and Genomic Sciences, School of Biological Institute of Human Genetics, Technische Universität München, Sciences, University of Manchester, Manchester, UK Munich, Germany 10 4 Alder Hey Children’s Hospital NHS Foundation Trust, Institute of Medical Genetics and Applied Genomics, University of Liverpool, UK Tübingen, Tübingen, Germany 5 University Children’s Hospital, University Medical Center 11 Institute of Human Genetics, University Medical Center Hamburg-Eppendorf, Hamburg, Germany Hamburg-Eppendorf, Hamburg, Germany Neurogenetics their own circular, double-stranded 16,569 bp genome, prokaryotic protein synthesis, with roles in the translocation of encoding 22 transfer RNAs (tRNAs), 2 ribosomal RNAs the ribosome during elongation and ribosome recycling upon (rRNAs) and 13 polypeptides [1]. All OXPHOS components, termination or stalling of translation [16]. In human mitochon- with the exception of complex II, are under bi-genomic con- dria, the dual roles of prokaryotic EF-G are carried out by the trol and as such are the product of both nuclear DNA and two distinct human homologs. Human mtEFG1 acts as an mitochondrial DNA (mtDNA)-encoded proteins [2]. Nuclear elongation factor with mitoribosome translocation activity, genes also encode the proteins responsible for mtDNA main- while mtEFG2 functions at the termination step of translation tenance, mitochondrial transcription and translation and all to disassemble the mitoribosome and allow subsequent cycles other mitochondrial processes. As a consequence, mutations of mitochondrial protein synthesis [17]. in either mitochondrial or nuclear genes may compromise Seventeen mitochondrial disease patients with GFM1 mu- ATP synthesis and cause mitochondrial disease. Extensive tations across 13 families have been described in the literature clinical and genetic heterogeneity makes the identification, so far. Earlier cases were associated with very severe systemic characterisation and diagnosis of mitochondrial disease chal- disease with early or neonatal onset, resulting in death within lenging, because clinical features often overlap with other the first 2 years of life. Some clinical features, such as micro- neurological or systemic diseases. The advent of next- cephaly, liver disease and encephalopathy, were common to generation sequencing, specifically whole exome sequencing multiple cases. However, more recent publications have de- (WES), has improved the identification of disease-causing scribed a new, milder, disease progression associated with pathogenic variants in many different genes resulting in a GFM1 mutations, with survival at 6 and 7 years of age [18, 19]. much greater diagnostic yield than previous candidate gene Two families with gene defects in GFM2, identified screening approaches [3]. through whole exome sequencing, have previously been de- Mutations in genes involved in the translation of mtDNA scribed in the literature associated with Leigh syndrome, mi- are well-documented causes of mitochondrial disease [4, 5]. crocephaly, simplified brain gyral pattern and insulin- These genetic variants characteristically lead to combined dependent diabetes [20, 21]. Here we present two unrelated OXPHOS deficiencies. The spectrum of resulting clinical phe- patients with previously unreported variants in GFM2, notypes is broad, often manifesting as multi-system disease documenting OXPHOS deficiencies in different tissues and with the heart, skeletal muscle, brain and liver commonly af- expanding the clinical phenotypes associated with GFM2-re- fected [6]. The translational machinery within mitochondria is lated mitochondrial disease. distinct to that of the cytosol and has several features which are reminiscent of the system employed in prokaryotic protein synthesis. This is reflective of the evolutionary origins of mi- Patients and methods tochondria as an endosymbiont α-proteobacterium [7]. Mitochondria possess their own mitoribosome which is a com- All studies were completed according to local Ethical bination of 12S and 16S rRNAs, encoded within the mitochon- Approval of the Institutional Review Boards of Newcastle drial genome, and at least 80 nuclear genes encode the proteins University (the National Research Ethics Service Committee that form the large and small mitoribosomal subunits [8]. North East—Newcastle & North Tyneside 1) and of the Pathogenic variants have been described in several of the Technische Universität München. In agreement with the mitoribosomal subunits [9–11]. Mitochondrial translation de- Declaration
Load more

Recommended publications
  • Neuromuscular Disorders Neurology in Practice: Series Editors: Robert A
    Neuromuscular Disorders neurology in practice: series editors: robert a. gross, department of neurology, university of rochester medical center, rochester, ny, usa jonathan w. mink, department of neurology, university of rochester medical center,rochester, ny, usa Neuromuscular Disorders edited by Rabi N. Tawil, MD Professor of Neurology University of Rochester Medical Center Rochester, NY, USA Shannon Venance, MD, PhD, FRCPCP Associate Professor of Neurology The University of Western Ontario London, Ontario, Canada A John Wiley & Sons, Ltd., Publication This edition fi rst published 2011, ® 2011 by Blackwell Publishing Ltd Blackwell Publishing was acquired by John Wiley & Sons in February 2007. Blackwell’s publishing program has been merged with Wiley’s global Scientifi c, Technical and Medical business to form Wiley-Blackwell. Registered offi ce: John Wiley & Sons Ltd, The Atrium, Southern Gate, Chichester, West Sussex, PO19 8SQ, UK Editorial offi ces: 9600 Garsington Road, Oxford, OX4 2DQ, UK The Atrium, Southern Gate, Chichester, West Sussex, PO19 8SQ, UK 111 River Street, Hoboken, NJ 07030-5774, USA For details of our global editorial offi ces, for customer services and for information about how to apply for permission to reuse the copyright material in this book please see our website at www.wiley.com/wiley-blackwell The right of the author to be identifi ed as the author of this work has been asserted in accordance with the UK Copyright, Designs and Patents Act 1988. All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, except as permitted by the UK Copyright, Designs and Patents Act 1988, without the prior permission of the publisher.
    [Show full text]
  • Supplementary Materials
    Supplementary materials Supplementary Table S1: MGNC compound library Ingredien Molecule Caco- Mol ID MW AlogP OB (%) BBB DL FASA- HL t Name Name 2 shengdi MOL012254 campesterol 400.8 7.63 37.58 1.34 0.98 0.7 0.21 20.2 shengdi MOL000519 coniferin 314.4 3.16 31.11 0.42 -0.2 0.3 0.27 74.6 beta- shengdi MOL000359 414.8 8.08 36.91 1.32 0.99 0.8 0.23 20.2 sitosterol pachymic shengdi MOL000289 528.9 6.54 33.63 0.1 -0.6 0.8 0 9.27 acid Poricoic acid shengdi MOL000291 484.7 5.64 30.52 -0.08 -0.9 0.8 0 8.67 B Chrysanthem shengdi MOL004492 585 8.24 38.72 0.51 -1 0.6 0.3 17.5 axanthin 20- shengdi MOL011455 Hexadecano 418.6 1.91 32.7 -0.24 -0.4 0.7 0.29 104 ylingenol huanglian MOL001454 berberine 336.4 3.45 36.86 1.24 0.57 0.8 0.19 6.57 huanglian MOL013352 Obacunone 454.6 2.68 43.29 0.01 -0.4 0.8 0.31 -13 huanglian MOL002894 berberrubine 322.4 3.2 35.74 1.07 0.17 0.7 0.24 6.46 huanglian MOL002897 epiberberine 336.4 3.45 43.09 1.17 0.4 0.8 0.19 6.1 huanglian MOL002903 (R)-Canadine 339.4 3.4 55.37 1.04 0.57 0.8 0.2 6.41 huanglian MOL002904 Berlambine 351.4 2.49 36.68 0.97 0.17 0.8 0.28 7.33 Corchorosid huanglian MOL002907 404.6 1.34 105 -0.91 -1.3 0.8 0.29 6.68 e A_qt Magnogrand huanglian MOL000622 266.4 1.18 63.71 0.02 -0.2 0.2 0.3 3.17 iolide huanglian MOL000762 Palmidin A 510.5 4.52 35.36 -0.38 -1.5 0.7 0.39 33.2 huanglian MOL000785 palmatine 352.4 3.65 64.6 1.33 0.37 0.7 0.13 2.25 huanglian MOL000098 quercetin 302.3 1.5 46.43 0.05 -0.8 0.3 0.38 14.4 huanglian MOL001458 coptisine 320.3 3.25 30.67 1.21 0.32 0.9 0.26 9.33 huanglian MOL002668 Worenine
    [Show full text]
  • Molecular Risk Factors of Pulmonary Arterial Hypertension Hamza M
    Florida International University FIU Digital Commons FIU Electronic Theses and Dissertations University Graduate School 9-22-2017 Molecular Risk Factors of Pulmonary Arterial Hypertension Hamza M. Assaggaf Florida International University, [email protected] DOI: 10.25148/etd.FIDC004013 Follow this and additional works at: https://digitalcommons.fiu.edu/etd Part of the Environmental Public Health Commons Recommended Citation Assaggaf, Hamza M., "Molecular Risk Factors of Pulmonary Arterial Hypertension" (2017). FIU Electronic Theses and Dissertations. 3554. https://digitalcommons.fiu.edu/etd/3554 This work is brought to you for free and open access by the University Graduate School at FIU Digital Commons. It has been accepted for inclusion in FIU Electronic Theses and Dissertations by an authorized administrator of FIU Digital Commons. For more information, please contact [email protected]. FLORIDA INTERNATIONAL UNIVERSITY Miami, Florida MOLECULAR RISK FACTORS OF PULMONARY ARTERIAL HYPERTENSION A dissertation submitted in partial fulfillment of the requirements for the degree of DOCTOR OF PHILOSOPHY in PUBLIC HEALTH by Hamza Assaggaf 2017 To: Dean Tomás R. Guilarte Robert Stempel College of Public Health and Social Work This dissertation, written by Hamza Assaggaf, entitled Molecular Risk Factors of Pulmonary Arterial Hypertension, having been approved in respect to style and intellectual content, is referred to you for judgment. We have read the dissertation and recommend that it be approved. __________________________________________ Alok Deoraj __________________________________________ Juan Luizzi __________________________________________ Deodutta Roy __________________________________________ ChangwonYoo, Co-Major Professor __________________________________________ Quentin Felty, Co-Major Professor Date of Defense: September 22, 2017 The dissertation of Hamza Assaggaf is approved. __________________________________________ Dean Tomás R. Guilarte Robert Stempel College of Public Health and Social Work __________________________________________ Andres G.
    [Show full text]
  • Journal of Agric. 2011 Vol. 11 No. 1
    ISSN: Journal of Print - 2277 - 0755 Agricultural Online - 2315 - 7453 Science © FUNAAB 2011 and Environment PHYLOGENETICS OF ELONGATION FACTOR-G MITOCHONDRIAL PROTEIN GENE (GFM1) IN TEN SELECTED SPECIES A.T. ABOLUDE1, O. OLOWOFESO*1, S.O. PETERS1, 3, M.O. OZOJE1, O.F. SMITH2 AND A.S. ADENAIKE1 1Department of Animal Breeding & Genetics, 2Department of Animal Physiology, Federal University of Agriculture, Abeokuta, Postcode 110001. Nigeria. 3Department of Animal and Range Sciences, New Mexico State University, Las Cruces, NM 88003, USA Corresponding author: [email protected] Tel:+2348060223098 ABSTRACT The second stage of protein synthesis is elongation. One of the elongation factors in the elongation cycle of protein synthesis is the elongation factor-G (GFM1). GFM1 is an ancient translational GTPase (trGTPase); the bacterial homolog of eukaryotic eEF2 and archaeal aEF2, respectively. It may interact with the transcriptional apparatus as a positive regulator of RNA synthesis in various species. Genetic variations in GFM1 gene of ten species including cattle, human, chicken, mouse, rat, horse, zebra fish, honeybee, pig and rabbit based on availability were investigated using bioinformatic approach. Using a comparative genomic approach, 4,442 base pairs (bp) of the GFM1 sequences were obtained. Align- ment of the sequences within the region of 3,626 bp and containing 816 gaps was carried out using Clustal W software. A very close relationship between rabbit and pig was observed in the phylogenetic tree of GFM1 gene which showed that the comparability of GFM1 gene sequence was highest be- tween the two species and they evolved from a most recent common ancestor with respect to GFM1 gene.
    [Show full text]
  • Mitochondrial Medicine 2019: Washington DC 6FLHQWLÀFDQG&OLQLFDO0HHWLQJV June 26-29, 2019 Hilton Alexandria Mark Center Alexandria, VA
    Mitochondrial Medicine 2019: Washington DC 6FLHQWLÀFDQG&OLQLFDO0HHWLQJV June 26-29, 2019 Hilton Alexandria Mark Center Alexandria, VA 2019 Course Chairs: Amel Karaa, MD and Carla Koehler, PhD 2019 CME Chair: Bruce H. Cohen, MD Mitochondrial Medicine 2019: Washington DC 6FLHQWLÀF&OLQLFDO3URJUDP June 26-29, 2019 Course Description The United Mitochondrial Disease Foundation and PeerPoint Medical Education Institute have joined efforts to sponsor and organize a CME-accredited symposium. Mitochondrial diseases are more common than previously recognized and mitochondrial pathophysiology is now a recognized part of many disease processes, including heart disease, cancer, AIDS and diabetes. There have been significant advances in the molecular genetics, proteomics, epidemiology and clinical aspects of mitochondrial pathophysiology. This conference is directed toward the scientist and clinician interested in all aspects of mitochondrial science. The content of this educational program was determined by rigorous assessment of educational needs and includes surveys, program feedback, expert faculty assessment, literature review, medical practice, chart review and new medical knowledge. The format will include didactic lectures from invited experts intermixed with peer-reviewed platform presentations. There will be ample time for professional discussion both in and out of the meeting room, and peer-reviewed poster presentations will be given throughout the meeting. This will be a four-day scientific meeting aimed at those with scientific and clinical
    [Show full text]
  • Compound Heterozygous GFM2 Mutations with Leigh Syndrome Complicated by Arthrogryposis Multiplex Congenita
    Journal of Human Genetics (2015) 60, 509–513 & 2015 The Japan Society of Human Genetics All rights reserved 1434-5161/15 www.nature.com/jhg ORIGINAL ARTICLE Compound heterozygous GFM2 mutations with Leigh syndrome complicated by arthrogryposis multiplex congenita Shinobu Fukumura1, Chihiro Ohba2, Toshihide Watanabe3, Kimio Minagawa3, Masaru Shimura4, Kei Murayama4, Akira Ohtake5, Hirotomo Saitsu2, Naomichi Matsumoto2 and Hiroyuki Tsutsumi1 Defects in the mitochondrial translation apparatus can impair energy production in affected tissues and organs. Most components of this apparatus are encoded by nuclear genes, including GFM2, which encodes a mitochondrial ribosome recycling factor. A few patients with mutations in some of these genes have been reported to date. Here, we present two female siblings with arthrogryposis multiplex congenita, optic atrophy and severe mental retardation. The younger sister had a progressive cerebellar atrophy and bilateral neuropathological findings in the brainstem. Although her cerebrospinal fluid (CSF) levels of lactate and pyruvate were not increased, brain magnetic resonance spectroscopy showed a lactate peak. Additionally, her CSF lactate/pyruvate and serum beta-hydroxybutyrate/acetoacetate ratios were high, and levels of oxidative phosphorylation in skin fibroblasts were reduced. We therefore diagnosed Leigh syndrome. Genomic investigation confirmed the presence of compound heterozygous GFM2 mutations (c.206+4A4G and c.2029-1G4A) in both siblings, causing aberrant splicing with premature stop codons (p.Gly50Glufs*4
    [Show full text]
  • UNIVERSITY of CALIFORNIA, IRVINE Whole Exome Sequencing
    UNIVERSITY OF CALIFORNIA, IRVINE Whole Exome Sequencing Analysis of Individuals with Autism Spectrum Disorder THESIS submitted in partial satisfaction of the requirements for the degree of MASTER OF SCIENCE in Genetic Counseling by Andrea Lynn Procko Thesis Committee: Professor John Jay Gargus, MD, PhD, Chair Professor Pamela Flodman. MSc, MS Professor Moyra Smith, MD, PhD 2016 © 2016 Andrea Lynn Procko DEDICATION For the families who participated in this study and for all the families who let me participate in their care, my sincerest gratitude. ii TABLE OF CONTENTS Page LIST OF FIGURES vi LIST OF TABLES vii ACKNOWLEDGMENTS viii ABSTRACT OF THE THESIS x INTRODUCTION 1 AUTISM SPECTRUM DISORDER 1 CLINICAL PHENOTYPE OF ASD 3 CORE DOMAINS 3 COMORBIDITIES 4 DIAGNOSIS OF ASD 5 ETIOLOGY OF ASD 6 ASD IN THE GENETICS CLINIC 10 EMERGING GENETIC TESTING FOR ASD 12 THE IMPORTANCE OF DETERMINING ETIOLOGY 14 SUMMARY OF RESEARCH PROGRAM 17 AIMS OF THIS STUDY 18 METHODS 19 NEURBIOLOGY AND GENETICS OF AUTISM STUDY 19 iii AIM I: FILTERING AND CHARACTERIZATION OF POTENTIAL DE NOVO 21 VARIANTS AIM II: TARGETED ANALYSIS OF PROBAND BASED ON CLINICAL 25 FINDINGS RESULTS 26 • AIM I: FILTERING AND CHARACTERIZATION OF POTENTIAL DE NOVO VARIANTS 26 DEMOGRAPHICS OF PARTICIPANTS 26 VARIANT FILTERING 27 PRIORITIZED VARIANTS 34 AU0002-0201 34 I. UNC5B 34 AU0005-0202 36 I. ASTN2 36 II. RNF31 38 III. GET4 39 AU0238-0201 40 I. ST6GAL2 40 II. SUFU 42 AUO243-0201 44 I. BMPR1B 44 II. TMEM8A 45 AU0245-0201 46 I. DPF3 46 II. EPHB2 48 III. TYRO3 49 IV.
    [Show full text]
  • THE USE of WHOLE EXOME SEQUENCING to DETECT NOVEL GENETIC DISORDERS: TWO CASES and an ASSESSMENT of the TECHNOLOGY by Lauren
    THE USE OF WHOLE EXOME SEQUENCING TO DETECT NOVEL GENETIC DISORDERS: TWO CASES AND AN ASSESSMENT OF THE TECHNOLOGY by Lauren Westerfield BS Psychology, Florida State University, 2011 Submitted to the Graduate Faculty of Graduate School of Public Health in partial fulfillment of the requirements for the degree of Master of Science University of Pittsburgh 2013 UNIVERSITY OF PITTSBURGH Graduate School of Public Health This thesis was presented by Lauren Westerfield It was defended on March 26, 2013 and approved by Robin Grubs, Ph.D., Assistant Professor, Department of Human Genetics, Graduate School of Public Health, University of Pittsburgh M. Michael Barmada, Ph.D., Associate Professor, Department of Human Genetics, Graduate School of Public Health, University of Pittsburgh Thesis Director: Gerard Vockley, M.D., Ph.D., Professor, Department of Pediatrics, School of Medicine, University of Pittsburgh ii Copyright © by Lauren Westerfield 2013 iii THE USE OF WHOLE EXOME SEQUENCING TO DETECT NOVEL GENETIC DISORDERS: TWO CASES AND AN ASSESSMENT OF THE TECHNOLOGY Lauren Westerfield, MS University of Pittsburgh, 2013 ABSTRACT Over the past several years whole exome sequencing (WES) by high-throughput sequencing of target-enriched genomic DNA has become both technically feasible and financially practical as a means of studying Mendelian disorders. It is also entering the clinical realm as a powerful diagnostic tool for cases that have eluded answers and a cost effective one for cases with a suspected genetically heterogeneous disorder or set of differentials. This thesis examines the strategies for use and impact of such a technology in both the research and clinical setting. It presents an analysis of two cases in which WES was used to determine the causative mutation in the phenotype of an unknown/undiagnosed genetic disorder.
    [Show full text]
  • Mutations of Human NARS2, Encoding the Mitochondrial Asparaginyl-Trna Synthetase, Cause Nonsyndromic Deafness and Leigh Syndrome
    UC Irvine UC Irvine Previously Published Works Title Mutations of human NARS2, encoding the mitochondrial asparaginyl-tRNA synthetase, cause nonsyndromic deafness and Leigh syndrome. Permalink https://escholarship.org/uc/item/2dt5r3jw Journal PLoS genetics, 11(3) ISSN 1553-7390 Authors Simon, Mariella Richard, Elodie M Wang, Xinjian et al. Publication Date 2015-03-25 DOI 10.1371/journal.pgen.1005097 License https://creativecommons.org/licenses/by/4.0/ 4.0 Peer reviewed eScholarship.org Powered by the California Digital Library University of California RESEARCH ARTICLE Mutations of Human NARS2, Encoding the Mitochondrial Asparaginyl-tRNA Synthetase, Cause Nonsyndromic Deafness and Leigh Syndrome Mariella Simon1,2☯, Elodie M. Richard3☯, Xinjian Wang4☯, Mohsin Shahzad3, Vincent H. Huang4, Tanveer A. Qaiser5, Prasanth Potluri6, Sarah E. Mahl7, Antonio Davila8, Sabiha Nazli5, Saege Hancock9, Margret Yu10, Jay Gargus11, Richard Chang2, a11111 Nada Al-sheqaih12, William G. Newman12, Jose Abdenur2, Arnold Starr13, Rashmi Hegde14, Thomas Dorn15, Anke Busch16, Eddie Park1, Jie Wu17, Hagen Schwenzer18, Adrian Flierl19, Catherine Florentz18, Marie Sissler18, Shaheen N. Khan5, Ronghua Li4, Min-Xin Guan4, Thomas B. Friedman20, Doris K. Wu21, Vincent Procaccio22, Sheikh Riazuddin23,24,25, Douglas C. Wallace6, Zubair M. Ahmed3, Taosheng Huang4*, Saima Riazuddin3* 1 Department of Developmental and Cellular Biology, School of Biological Sciences, University of California, Irvine, Irvine, California, United States of America, 2 CHOC Childrens’, Division of Metabolics, Orange, OPEN ACCESS California, United States of America, 3 Department of Otorhinolaryngology Head & Neck Surgery, School of Medicine, University of Maryland, Baltimore, Maryland, United States of America, 4 Division of Human Citation: Simon M, Richard EM, Wang X, Shahzad Genetics, Cincinnati Children’s Hospital Medical Center, Cincinnati, Ohio, United States of America, M, Huang VH, Qaiser TA, et al.
    [Show full text]
  • Genes and Variants Underlying Human Congenital Lactic Acidosis—From Genetics to Personalized Treatment
    Journal of Clinical Medicine Article Genes and Variants Underlying Human Congenital Lactic Acidosis—From Genetics to Personalized Treatment Irene Bravo-Alonso 1, Rosa Navarrete 1, Ana Isabel Vega 1, Pedro Ruíz-Sala 1, María Teresa García Silva 2, Elena Martín-Hernández 2, Pilar Quijada-Fraile 2, Amaya Belanger-Quintana 3, Sinziana Stanescu 3, María Bueno 4, Isidro Vitoria 5 , Laura Toledo 6, María Luz Couce 7 , Inmaculada García-Jiménez 8, Ricardo Ramos-Ruiz 9 , Miguel Ángel Martín 10 , Lourdes R. Desviat 1, Magdalena Ugarte 1, Celia Pérez-Cerdá 1, Begoña Merinero 1, Belén Pérez 1,* and Pilar Rodríguez-Pombo 1,* 1 Centro de Diagnóstico de Enfermedades Moleculares, Centro de Biología Molecular Severo Ochoa, UAM-CSIC, CIBERER, IDIPAZ, 28049 Madrid, Spain; [email protected] (I.B.-A.); [email protected] (R.N.); [email protected] (A.I.V.); [email protected] (P.R.-S.); [email protected] (L.R.D.); [email protected] (M.U.); [email protected] (C.P.-C.); [email protected] (B.M.) 2 Unidad de Enfermedades Mitocondriales y Enfermedades Metabólicas Hereditarias, Hospital Universitario 12 de Octubre, CIBERER, 28041 Madrid, Spain; [email protected] (M.T.G.S.); [email protected] (E.M.-H.); [email protected] (P.Q.-F.) 3 Unidad de Enfermedades Metabólicas Congénitas, Hospital Universitario Ramón y Cajal, 28034 Madrid, Spain; [email protected] (A.B.-Q.); [email protected] (S.S.) 4 Dpto. de Pediatría, Hospital Universitario Virgen del Rocío, 28034 Sevilla, Spain;
    [Show full text]
  • Wasin Vol. 9 N. 4 2558.Pmd
    Asian Biomedicine Vol. 9 No. 4 August 2015; 455 - 471 DOI: 10.5372/1905-7415.0904.415 Original article Antiaging phenotype in skeletal muscle after endurance exercise is associated with the oxidative phosphorylation pathway Wasin Laohavinija, Apiwat Mutirangurab,c aFaculty of Medicine, Chulalongkorn University, Bangkok 10330, Thailand bDepartment of Anatomy, Faculty of Medicine, Chulalongkorn University, Bangkok 10330, Thailand cCenter of Excellence in Molecular Genetics of Cancer and Human Diseases, Chulalongkorn University, Bangkok 10330, Thailand Background: Performing regular exercise may be beneficial to delay aging. During aging, numerous biochemical and molecular changes occur in cells, including increased DNA instability, epigenetic alterations, cell-signaling disruptions, decreased protein synthesis, reduced adenosine triphosphate (ATP) production capacity, and diminished oxidative phosphorylation. Objectives: To identify the types of exercise and the molecular mechanisms associated with antiaging phenotypes by comparing the profiles of gene expression in skeletal muscle after various types of exercise and aging. Methods: We used bioinformatics data from skeletal muscles reported in the Gene Expression Omnibus repository and used Connection Up- and Down-Regulation Expression Analysis of Microarrays to identify genes significant in antiaging. The significant genes were mapped to molecular pathways and reviewed for their molecular functions, and their associations with molecular and cellular phenotypes using the Database for Annotation,
    [Show full text]
  • Novel GFM2 Variants Associated with Early-Onset Neurological Presentations of Mitochondrial Disease and Impaired Expression of OXPHOS Subunits
    Glasgow RIC, Thompson K, Barbosa IA, He L, Alston CL, Deshpande C, Simpson MA, Morris AAM, Neu A, Löbel U, Hall J, Prokisch H, Haack TB, Hempel M, McFarland R, Taylor RW. Novel GFM2 variants associated with early-onset neurological presentations of mitochondrial disease and impaired expression of OXPHOS subunits. Neurogenetics 2017, DOI: 10.1007/s10048-017-0526-4 Copyright: © The Author(s) 2017. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License, which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. DOI link to article: https://doi.org/10.1007/s10048-017-0526-4 Date deposited: 02/11/2017 This work is licensed under a Creative Commons Attribution 4.0 International License Newcastle University ePrints - eprint.ncl.ac.uk Neurogenetics https://doi.org/10.1007/s10048-017-0526-4 ORIGINAL ARTICLE Novel GFM2 variants associated with early-onset neurological presentations of mitochondrial disease and impaired expression of OXPHOS subunits Ruth I. C. Glasgow1 & Kyle Thompson1 & Inês A. Barbosa2 & Langping He1 & Charlotte L. Alston1 & Charu Deshpande2 & Michael A. Simpson2 & Andrew A. M. Morris3,4 & Axel Neu5 & Ulrike Löbel 6 & Julie Hall7 & Holger Prokisch8,9 & Tobias B. Haack9,10 & Maja Hempel11 & Robert McFarland1 & Robert W. Taylor1 Received: 22 September 2017 /Accepted: 3 October 2017 # The Author(s) 2017. This article is an open access publication Abstract Mitochondrial diseases are characterised by clini- demonstrate the effects of defective mtEFG2 function, caused cal, molecular and functional heterogeneity, reflecting their bi- by previously unreported variants, confirming pathogenicity genomic control.
    [Show full text]